Nima Farzan named Latigo CEO

Latigo Biotherapeutics, a privately-held US biotech focused on developing non-opioid pain medicines, has appointed Nima Farzan as chief executive.

Mr Farzan has more than two decades of leadership experience in the biopharmaceutical industry. He replaces Desmond Padhi, operating partner at Westlake Village BioPartners, who has been serving as Latigo’s interim chief executive.

Prior to this appointment, Mr Farzan was chief executive of Kinnate Biopharma, a company he joined in 2020, building an organization that subsequently brought three different precision oncology compounds discovered internally into the clinic. He led the firm’s successful initial public offering (IPO) of $270 million and eventual sale to Xoma Corporation (Nasdaq: XOMA) in April of this year.